The Alzheimer’s disease–linked protease BACE2 cleaves VEGFR3 and modulates its signaling
Authors:
- Andree SchmidtASAndree Schmidt
- Brian HrupkaBHBrian Hrupka
- Frauke van BebberFBFrauke van Bebber
- Xiao FengXFXiao Feng
- Sarah K. TschirnerSTSarah K. Tschirner
- Marlene AßfalgMAMarlene Aßfalg
- Stephan A. MüllerSMStephan A. Müller
- Laura Sophie HilgerLHLaura Sophie Hilger
- Laura I. HofmannLHLaura I. Hofmann
- Martina PigoniMPMartina Pigoni
- Georg JocherGJGeorg Jocher
Open Access
- 18 June 2024
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (16)
Abstract
The β-secretase β-site APP cleaving enzyme (BACE1) is a central drug target for Alzheimer’s disease. Clinically tested, BACE1-directed inhibitors also block the homologous protease BACE2. Yet little is known about physiological BACE2 substrates and functions in vivo. Here, we identify BACE2 as the protease shedding the lymphangiogenic vascular endothelial growth factor receptor 3 (VEGFR3). Inactivation of BACE2, but not BACE1, inhibited shedding of VEGFR3 from primary human lymphatic endothelial cells (LECs) and reduced release of the shed, soluble VEGFR3 (sVEGFR3) ectodomain into the blood of mice, nonhuman primates, and humans. Functionally, BACE2 inactivation increased full-length VEGFR3 and enhanced VEGFR3 signaling in LECs and also in vivo in zebrafish, where enhanced migration of LECs was observed. Thus, this study identifies BACE2 as a modulator of lymphangiogenic VEGFR3 signaling and demonstrates the utility of sVEGFR3 as a pharmacodynamic plasma marker for BACE2 activity in vivo, a prerequisite for developing BACE1-selective inhibitors for safer prevention of Alzheimer’s disease.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (263531414/FOR2290)
- Munich Cluster for Systems Neurology (390857198)
- Deutsche Forschungsgemeinschaft (CRC 1348)
- Bundesministerium für Forschung, Technologie und Raumfahrt (01ED2002B)
- Bundesministerium für Forschung, Technologie und Raumfahrt (CLINSPECT-M)
- Helmholtz-Gemeinschaft (DEEPROAD)
- Institute for the Promotion of Innovation by Science and Technology (IWT145058)
- Alzheimer's Association (SG-23-1029755 BACE)
This publication has 73 references indexed in Scilit:
- The β-Secretase BACE1 in Alzheimer’s DiseaseBiological Psychiatry, 2021
- Single-Cell Transcriptome Atlas of Murine Endothelial CellsCell, 2020
- Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer DiseaseJAMA Neurology, 2020
- A Close Look at BACE1 Inhibitors for Alzheimer’s Disease TreatmentCNS Drugs, 2019
- How to Plumb a Pisces: Understanding Vascular Development and Disease Using Zebrafish EmbryosDevelopmental Cell, 2017
- The Skyline ecosystem: Informatics for quantitative mass spectrometry proteomicsMass Spectrometry Reviews, 2017
- Label‐free quantitative analysis of the membrane proteome of Bace1 protease knock‐out zebrafish brainsProteomics, 2013
- FLT4/VEGFR3and Milroy Disease: Novel Mutations, a Review of Published Variants and Database UpdateHuman Mutation, 2012
- Bace2 Is a β Cell-Enriched Protease that Regulates Pancreatic β Cell Function and MassCell Metabolism, 2011
- Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: Correlation with clinical parameters and outcomeEuropean Journal of Cancer, 2009